Tamara Vervloessem

The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca 2+ signaling

Tamara Vervloessem, Hristina Ivanova, Tomas Luyten et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 2016 · 40 citations · Full text

Life Sciences, Cell Biology, Pharmacology +12

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax

Tamara Vervloessem, Haidar Akl, Thomas Tousseyn et al. · Oncotarget · 2017 · 26 citations · Full text

Medicine, Oncology, Pharmacology +17

BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models

Tamara Vervloessem, Binu K. Sasi, Elena Xerxa et al. · Cell Death and Disease · 2020 · 26 citations · Full text

Medicine, Oncology, Pharmacology +14

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition

Martijn Kerkhofs, Tamara Vervloessem, Kinga B. Stopa et al. · Biomolecules · 2020 · 13 citations · Full text

Medicine, Oncology, Pharmacology +15

Recent advances in uncovering the mechanisms contributing to BIRD-2-induced cell death in B-cell cancer cells

Martijn Kerkhofs, Tamara Vervloessem, Mart Bittremieux et al. · Cell Death and Disease · 2019 · 12 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +16